Product Reports Resources Pricing Login Book a demo

Akero Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2017 · IPO 2019

Akero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH), a severe liver disease affecting millions globally. The company's lead product, AKR-001, is designed to address NASH holistically by reducing liver fat, inflammation, and fibrosis, while also improving lipoprotein profiles to lower cardiovascular risks. Akero operates in the healthcare and pharmaceutical market, targeting patients with NASH and related metabolic disorders. The business model revolves around research and development of therapeutic candidates, progressing through clinical trials, and eventually seeking regulatory approval for commercialization. Revenue is generated through partnerships, licensing agreements, and future product sales. Keywords: biopharmaceutical, NASH, liver disease, AKR-001, metabolic balance, fibrosis, inflammation, lipoprotein, cardiovascular, clinical trials.

Valuation $3.76B
Total funding $100–500M
Power Law Unicorn$1–10B valuation tier

Investors

20 investors on Akero Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 11 investors entered at this stage
Versant Ventures
venBio Partners
Atlas Venture
Apple Tree Partners
Janus Henderson Investors
BVF Partners
Cormorant Asset Management
LifeSci Venture Partners
Redmile Group
Rock Springs Capital
Boxer Capital
Series B+ 9 investors entered at this stage
Hercules Capital
Pfizer
Adage Capital
General Atlantic
T. Rowe Price
Avidity Partners
Commodore Capital
Perceptive Advisors
Logos Capital

Global footprint

Where Akero Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.4%
🇮🇳 India1.6%
2 countries shown
Web traffic by country
7K monthly visits
across markets
🇺🇸 United States100%
Top 1 markets shown

Talent graph

The shape of Akero Therapeutics's talent

Dealroom maps Akero Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 team members profilednamed & role-tagged by Dealroom
75 employeestotal headcount
2 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Akero Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$130k patent portfolio · 4 active families

Estimated portfolio value
$130k
<0.01% of market cap · 455.9× smaller than top peer Akeso Biopharma ($59M)
4 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Akero Therapeutics

An AI-synthesized read of the highest-engagement posts about Akero Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Akero Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles